Mar Vista Investment Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-207
Closed -$25K 39
2025
Q2
$25K Hold
207
﹤0.01% 46
2025
Q1
$23.1K Sell
207
-93
-31% -$9.9K ﹤0.01% 46
2024
Q4
$29.2K Hold
300
﹤0.01% 46
2024
Q3
$34.5K Hold
300
﹤0.01% 46
2024
Q2
$31.9K Sell
300
-51,375
-99% -$5.16M ﹤0.01% 50
2024
Q1
$5M Hold
51,675
0.22% 37
2023
Q4
$5.22M Hold
51,675
0.24% 37
2023
Q3
$5.26M Hold
51,675
0.25% 35
2023
Q2
$5.21M Buy
51,675
+14
+0% +$1.4K 0.22% 36
2023
Q1
$4.75M Buy
51,661
+1,582
+3% +$138K 0.21% 36
2022
Q4
$4.54M Buy
50,079
+3,030
+6% +$255K 0.2% 37
2022
Q3
$3.58M Sell
47,049
-925
-2% -$76.7K 0.16% 37
2022
Q2
$4.05M Hold
47,974
0.17% 39
2022
Q1
$4.21M Buy
47,974
+5,511
+13% +$477K 0.13% 38
2021
Q4
$3.71M Sell
42,463
-95
-0.2% -$7.89K 0.1% 42
2021
Q3
$3.48M Hold
42,558
0.09% 42
2021
Q2
$3.88M Hold
42,558
0.1% 43
2021
Q1
$3.64M Buy
42,558
+8
+0% +$718 0.08% 43
2020
Q4
$4.02M Hold
42,550
0.1% 41
2020
Q3
$3.7M Buy
42,550
+42,279
+15,601% +$3.66M 0.1% 39
2020
Q2
$24K Buy
271
+14
+5% +$1.21K ﹤0.01% 48
2020
Q1
$21K Buy
257
+74
+40% +$6.6K ﹤0.01% 50
2019
Q4
$17K Buy
+183
New +$16.4K ﹤0.01% 49

Other funds holding NVS

Mar Vista Investment Partners's NVS Position: Q3 2025 in Review

Mar Vista Investment Partners sold out of Novartis (NVS) in Q3 2025, closing a stake of 207 shares — an estimated $25K sold.

Mar Vista Investment Partners first reported a position in NVS in Q4 2019 and held it in 23 quarters. The position peaked at $5.26M in Q3 2023. 1,401 funds tracked by Wall St. Rank hold NVS as of Q3 2025.

  • Mar Vista Investment Partners reported no remaining Novartis position as of Q3 2025 after selling out during the quarter.
  • Mar Vista Investment Partners sold 207 Novartis shares in Q3 2025, an estimated $25K.
  • Mar Vista Investment Partners first reported a position in Novartis in Q4 2019 and held it in 23 quarters.
  • Mar Vista Investment Partners's Novartis position peaked at $5.26M in Q3 2023.
  • 1,401 funds tracked by Wall St. Rank held Novartis as of Q3 2025.

Based on Mar Vista Investment Partners's 13F filing for Q3 2025, filed 12 Nov 2025.